-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Glioblastoma, also known as polymorphic glioblastoma (GBM), is one of the most common and invasive brain cancers.
signs and symptoms of glioblastoma were initially nonse specific.
may experience headaches, personality changes, nausea, stroke-like symptoms, and symptoms usually worsen rapidly and may develop into confusion.
pharmaceutical company Denovo Biopharma announced today that the first patient in a Phase III clinical study has been treated to assess the effectiveness and safety of DB102 (enzastaurin) in combination with termosamine/radiotherapy as a first-line therapy for the initial treatment of polymorphic glioblastoma (GBM).
more than 300 patients in this randomized, double-blind, placebo-controlled global study, with an overall survival rate (OS) at the main endpoint.
the study has been approved by regulators in the US, Canada and China, and DB 102 was granted fda "fast track qualification" last year.
DB102 (enzastaurin) is a small molecular inhibitor of the PKC beta, PI3K and AKT pathways, and has been studied in 3,000 cases of solid and blood tumors.
one of the deadliest cancers, and first-line drug treatments continue to be dominated by methamphetamine," said Zane Yang, M.D., Chief Medical Officer, Denovo, U.S. Department of Medicine.
promising anti-cancer drugs, including anti-PD-1 antibodies, have failed to improve the efficacy of tymoamine.
I hope our innovative approach will bring new hope to GBM patients."
